Targeting a specific protein to improve treatment for ovarian cancer
Targeting EGFL6 in Ovarian Cancer
This study is looking at a protein called EGFL6 that is found in higher levels in the blood vessels of aggressive ovarian cancer tumors, and it's testing new treatments that target this protein to help improve outcomes for patients and make therapies less harsh.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10931363 on NIH RePORTER |
What this research studies
This research focuses on high-grade serous ovarian cancer, the most aggressive type of ovarian cancer, which often shows resistance to current therapies. The study investigates a protein called EGFL6, which is found in higher amounts in tumor blood vessels compared to normal tissues. By developing and testing new antibodies that target EGFL6, the researchers aim to improve treatment outcomes and reduce the adverse effects associated with existing therapies. The approach seeks to enhance the immune response against tumors and inhibit abnormal blood vessel growth in the tumor environment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-grade serous ovarian cancer who have not responded well to current therapies.
Not a fit: Patients with other types of ovarian cancer or those who are not eligible for experimental treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting angiogenesis in cancer treatment, but this specific approach targeting EGFL6 is novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.